Homepage > Company > Media > Pharma News > 2016 > Sanofi in talks with Actelion, sources say

Sanofi in talks with Actelion, sources say

French pharmaceutical company Sanofi is in talks with Swiss drugmaker Actelion, but a deal is not imminent, sources confirmed to CNBC on Wednesday.

U.S. shares of Actelion and Sanofi were down 9 percent and 2.5 percent, respectively, on Wednesday.

It's unclear what price Sanofi might pay or what structure is envisioned, but the deal could value Actelion as much as $30 billion, according to The Wall Street Journal, which first reported on the talks and cited people familiar with the matter.

On Tuesday, Johnson & Johnson ended its discussions with Actelion regarding a possible transaction. Actelion told J&J it was confident it could attract a higher offer than the 250 Swiss francs per share the U.S. company had offered, Reuters reported.

In August, Sanofi, eager for deals to broaden its drug lineup, was trumped by Pfizer's $14 billion bid for U.S. cancer drug company Medivation.

Dec, 14

Source: http://www.cnbc.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...